Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial performance with a 23% increase in EPS and significant regional growth, especially in Asia Pacific. The Q&A section reveals positive sentiment from analysts towards the company's operational margin expansion and future growth potential in emerging biotech and China. Despite not raising the full-year guidance, the company maintains confidence in achieving it. The strategic focus on margin optimization and strong performance in analytics and proteins further supports a positive outlook. However, some uncertainties remain regarding specific future impacts, slightly moderating the sentiment.
Key Financial Performance
Revenue $194 million for the first quarter, a 15% reported year-over-year increase (11% organic growth). Growth driven by healthy demand across all geographies and product franchises, with analytics leading at 50%+ growth.
Adjusted Gross Margin 55.5% for the first quarter, a 180 basis points increase year-over-year. Driven by volume leverage, pricing execution, and favorable product mix, offsetting inflation and tariffs.
Adjusted Operating Margin 15.4% for the first quarter, a 160 basis points increase year-over-year. Resulted from disciplined cost management and strong revenue growth.
Adjusted EBITDA $40 million for the first quarter, representing just under 21% adjusted EBITDA margin. Reflects strong operational performance.
Adjusted Net Income $27 million for the first quarter, a 22% year-over-year increase. Higher adjusted operating income offset slightly by lower interest income.
Adjusted Earnings Per Share (EPS) $0.48 for the first quarter, a 23% year-over-year increase. Reflects strong financial performance.
Cash and Marketable Securities $785 million at the end of the first quarter, up $17 million sequentially. Driven by $28 million of cash flow from operations, offset by $5 million of CapEx.
Regional Revenue Growth North America grew mid-single digits, EMEA grew more than 20%, and Asia Pacific grew more than 25%. Growth driven by strong performance in analytics, proteins, and ATFs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Analytics Franchise: Achieved 50%+ growth, driven by downstream analytics demand and SoloVPE PLUS placements. Expected 20%+ growth for the year.
Chromatography: Revenue increased over 25%, driven by OPUS columns. Expected 20%+ growth in 2026.
Proteins: Mid-teens growth led by ligands. Expected low double-digit growth for the year.
China Market Expansion: Revenue nearly doubled in China, marking the best quarter in over two years. Signed a new OEM partnership to enhance local manufacturing capabilities starting in 2027.
Asia Pacific Growth: Region grew over 25%, driven by ATFs, mixers, and analytics. Asia Pacific remains a key strategic region.
Transformation Office: Launched to optimize manufacturing, improve product profitability, enhance customer service, and accelerate IT modernization and AI implementation. Expected to deliver at least 1 point of annualized margin benefit by 2027.
Polymem Divestiture: Sold Polymem operation in France, which generated $7 million in revenue but operated at a net loss in 2025. This improves margin outlook.
IT Modernization and AI Implementation: Invested in IT and AI across legal, commercial, and supply chain functions. Integrated AI into analytics products for real-time data collection.
China OEM Partnership: Signed a multi-phase partnership to expand competitiveness and local manufacturing in China, starting in 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Polymem Business Divestiture: The Polymem business, which was a non-core and low-margin operation, was divested due to its net loss and limited alignment with bioprocessing. This could impact revenue by $7 million for the year, though it improves margin outlook.
Gene Therapy Headwinds: The gene therapy segment faced specific headwinds, diluting growth in new modalities. This could impact the filtration franchise, which is expected to grow only mid-single digits in 2026.
Customer Decision-Making Delays: The company noted slower customer decision-making, which could delay the conversion of opportunities in the capital equipment funnel.
Tariff Surcharges: The company expects a couple of million dollars in tariff surcharges in 2026, which could impact profitability.
ATF Timing Dynamics: Moderated ATF (Alternating Tangential Flow) outlook in 2026 due to customer-specific timing dynamics, with growth expected to return in 2027.
Middle East Conflict: Limited impact from the conflict in the Middle East is assumed, but it remains a potential risk to operations and revenue.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Revenue Guidance: Repligen expects 9% to 13% organic growth, with updated reported revenue guidance of $803 million to $833 million, reflecting the sale of the Polymem business.
Adjusted Earnings Per Share (EPS) Guidance: The company has increased its adjusted EPS guidance for the full year to $1.97 to $2.05, representing an 18% increase at the midpoint compared to 2025.
Gross Margin Expansion: Repligen anticipates 110 to 160 basis points of gross margin expansion for 2026, driven by favorable product mix, pricing execution, and the divestiture of Polymem.
Operating Margin Expansion: The company expects 160 to 200 basis points of operating margin expansion for 2026, with a 30 basis point increase at the midpoint compared to prior guidance.
Capital Expenditures (CapEx): CapEx spending is projected to be approximately 3% to 4% of 2026 revenue.
Filtration Segment Growth: Filtration is expected to grow mid-single digits in 2026, with a moderated ATF outlook due to customer-specific timing dynamics. Strong growth is anticipated to return in 2027.
Chromatography Segment Growth: Chromatography is projected to grow over 20% in 2026, driven by strong demand for OPUS pre-packed columns.
Proteins Segment Growth: Proteins are expected to grow at least in low double digits for 2026, supported by healthy demand across offerings.
Analytics Segment Growth: Analytics is forecasted to grow over 20% in 2026, driven by strong demand for downstream analytics and contributions from upstream analytics.
Transformation Office Initiatives: The newly established transformation office aims to deliver at least 1 point of annualized margin benefit by the end of 2027, focusing on manufacturing optimization, product profitability, and IT modernization.
China Market Expansion: Repligen has signed an OEM partnership to enhance local manufacturing capabilities in China starting in 2027, with expectations for multi-phase growth in the region.
Long-Term EBITDA Margin Target: The company aims to achieve a 30% adjusted EBITDA margin by 2030, with accelerated progress expected due to transformation initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you summarize the factors contributing to the operational margin expansion in Q1 and the role of the transformation office?
A:The operational margin expansion in Q1 was driven by volume leverage, price execution, and strong mix from analytics growth and filtration franchise. Timing of cost absorption also played a role. The transformation office focuses on Fit for Growth execution, margin improvement, and structured resource allocation. The initiative aims for a 1% annualized margin expansion by the end of 2027, with full benefits expected in 2028.
Q:What was the performance of capital equipment in Q1, and what were the notable trends?
A:Capital equipment increased year-on-year in Q1, driven by strength in analytics and mixers, particularly in China. Orders picked up significantly in the latter half of the quarter, and some RFPs from last year were won, indicating positive momentum.
Q:What is the outlook for emerging biotech, and what factors are influencing its recovery?
A:Emerging biotech showed over 20% growth in Q1, marking the fourth consecutive quarter of growth. While still below historical levels, improved biotech funding and positive clinical updates are expected to sustain growth. The segment contributed 8-9% of total sales in Q1 and is expected to return to 10% in the coming quarters.
Q:What drove the strong performance in China during Q1, and what is the outlook?
A:China nearly doubled its sales in Q1, driven by local demand and strength in mixers and filtration consumables. The OEM partnership has not yet impacted results but signals a strong commitment to the Chinese market. The funnel looks strong, and further growth is expected as the partnership develops.
Q:Why was the full-year guidance for 2026 not raised despite a strong Q1?
A:The full-year guidance was not raised due to moderated expectations for ATF in the second half, driven by customer inventory management and delayed commercial launches. However, the company remains confident in meeting its guidance and sees potential for high-end performance if consumables and equipment orders accelerate.
Q:What is the status and future potential of the ATF business?
A:ATF grew in Q1 in both capital and consumables. Temporary inventory management by two customers has moderated expectations for 2026, but the long-term runway remains strong. New product implementations and innovations are expected to drive growth, with significant tailwinds anticipated from 2027 onwards.
Q:What are the key drivers and future plans for the analytics business?
A:The analytics business grew 50% in Q1, driven by strong demand for process analytics and PAT technologies. Investments are being made in R&D for new product launches and upgrades. M&A opportunities are also being explored to complement the portfolio, and services attached to analytics are growing significantly.
Q:What is the company's strategy for the Chinese market?
A:The strategy focuses on partnering with local companies to regain market share and align with the growing local demand. The OEM partnership is a key step, with plans to expand collaborations further. The company aims to appear more localized to compete effectively in the evolving Chinese market.
Q:What are the company's plans for margin optimization through the transformation office?
A:The transformation office focuses on manufacturing footprint optimization, improving profitability of lower-margin products, IT modernization, and leveraging AI. These efforts aim to drive synergies, cost savings, and long-term margin expansion.
Q:What is the outlook for the protein business, and what are its growth drivers?
A:The protein business grew in Q1, driven by strong demand for ligands and collaboration with Purolite. The business is benefiting from multiple design-ins and has a strong runway for growth. Investments in R&D and customer collaborations are expected to sustain long-term growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timing of customer preparedness for large-scale equipment orders and the exact impact of the transformation office initiatives on individual product lines. Additionally, there was limited clarity on the competitive landscape for ATF and the specific contributions of new product launches in analytics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI expert
AI implementation
AI variety
China OEM
Fit journey
OEM relationship
OPUS
Olivier
President Investor
Repligen
Tier
Vice President
analytics franchise
analytics offering
basis ATF
chromatography
comparison
confidence outlook
country
demand portfolio
digit basis
digitization journey
expense
filtration system
focus area
function
geography
loss
priority
process intensification
protein digit
region Asia
sale Polymem
strength analytics
strength customer
therapy headwind
transformation office
RGEN Transcript
Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary shows strong financial performance with a 23% increase in EPS and significant regional growth, especially in Asia Pacific. The Q&A section reveals positive sentiment from analysts towards the company's operational margin expansion and future growth potential in emerging biotech and China. Despite not raising the full-year guidance, the company maintains confidence in achieving it. The strategic focus on margin optimization and strong performance in analytics and proteins further supports a positive outlook. However, some uncertainties remain regarding specific future impacts, slightly moderating the sentiment.
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call summary reveals strong financial performance with growth in key areas like Chromatography and Analytics, along with margin improvements. The Q&A section highlights positive future prospects, such as high funnel opportunities and strategic M&A considerations, despite some uncertainties. The guidance increase and strategic investments signal optimism. However, management's lack of clarity on certain topics tempers the sentiment slightly. Overall, the positive financial metrics and optimistic guidance outweigh these concerns, suggesting a positive stock price movement in the short term.
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Neutral12-3
RGEN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
